<DOC>
	<DOCNO>NCT02267278</DOCNO>
	<brief_summary>The goal clinical research study learn pracinostat , give combination ruxolitinib , help control MF . The safety drug combination also study .</brief_summary>
	<brief_title>Ruxolitinib Pracinostat Combination Therapy Patients With Myelofibrosis ( MF )</brief_title>
	<detailed_description>Study Drug Administration : If find eligible take part study , take ruxolitinib mouth 2 time day . You may take dose ruxolitinib without food . You also take pracinostat mouth 1 time day 3 alternating day ( example Monday , Wednesday , Friday Tuesday , Thursday , Saturday ) every 3 week start Day 1 Cycle 4 . You take dose pracinostat morning , 30 minute 2 hour meal . You swallow dose pracinostat whole cup water ( 8 ounce ) . You give study drug diary write take dose study drug miss vomit dos study drug . You must bring diary clinic Day 1 cycle end-of-treatment visit . You also need bring leftover pill empty container study drug clinic study doctor tell . Study Visits : There 28 day ( 4 week ) every study cycle . You visit MD Anderson regular study visit participate study Cycles 2-7 , every 3 cycle ( Cycles 10 , 13 , 16 , ) . Once Cycles 2-7 every 3 cycle ( Cycles 10 , 13 , 16 , ) : - You physical exam . - You complete questionnaire quality life . At visit Cycles 4 , 5 , 6 every 3 cycle start cycle 10 ( cycle 10 , 13 , 16 ) : You EKG check heart function . At visit Cycles 4 , 5 , 7 every 3 cycle ( Cycles 10 , 13 , 16 , ) blood ( 1-2 teaspoon ) draw cytokine testing . At visit Cycles 7 13 , every 6 cycle ( Cycles 19 , 25 , 31 , ) , doctor think need , bone marrow biopsy check status disease cytogenetic genetic testing . Every 2 week first 6 cycle every 2 4 week , blood ( 2-3 tablespoon ) draw routine test . In mandatory visit MD Anderson , may choose blood draw perform local lab clinic closer home . The result send study doctor . Length Treatment : You may continue take study drug 4 year . You longer able take study drug disease get bad , intolerable side effect occur , unable follow study direction . Your participation study follow-up . Follow-Up : About 30 day last dose study drug , receive another treatment MF , call study doctor member study staff ask side effect may . This call last 10 minute . This investigational study . Pracinostat FDA-approved commercially available . It currently use research purpose . Ruxolitinib FDA-approved commercially available treat MF . The study doctor explain study drug design work . Up 25 participant enrol study . All take part MD Anderson .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<criteria>1 . Diagnosis MF ( either primary post essential thrombocythemia/polycythemia vera ) require therapy , include previously treat relapsed refractory , newly diagnose , intermediate1 2 high risk accord International Prognostic Scoring System ( IPSS ) . 2 . Palpable splenomegaly equal 5 cm leave costal margin physical exam 3 . Understanding voluntary signing IRBapproved inform consent form . 4 . Age equal 18 year time signing informed consent . 5 . Diseasefree malignancy . 6 . ECOG performance status 0 2 . 7 . Negative pregnancy test female childbearing potential ( FCBP ) . Male patient female partner childbearing potential female patient childbearing potential require use two form acceptable contraception , include one barrier method , participation study 30 day follow last dose . Acceptable form contraception include 1 highly effective method intrauterine device ( IUD ) , hormonal ( birth control pill , injection , implant ) , tubal ligation , partner 's vasectomy least 1 additional approve barrier method latex condom , diaphragm , cervical cap . Female patient childbearing potential must breastfeed plan breast feed must negative pregnancy test ≤7 day first study treatment . 8 . QTcF interval equal less 470 msec 9 . Normal serum potassium magnesium level 10 . Adequate organ function demonstrate follow : Direct bilirubin equal le 2.0 mg/dL , Serum creatinine equal less 2.0 mg/dL. , SGPT equal less 3 x upper limit normal ( unless consider related MF patient know history Gilberts ) 11 . Platelets &gt; /= 50000/uL 12 . ANC &gt; /= 1000/uL 1 . Prior therapy JAK inhibitor ( ruxolitinib less 3 month duration currently ) HDACi . Patients currently ruxolitinib less 3 month therapy eligible . 2 . Use standard experimental therapy within 14 day start study therapy . 3 . Lack recovery toxicity previous therapy grade 1 baseline . 4 . Suspected pregnancy , pregnant lactating female . 5 . Any condition , include presence laboratory abnormality , opinion treat physician place subject unacceptable risk he/she participate study confounds ability interpret data study . 6 . Known positive HIV infectious hepatitis , type A , B C. 7 . Patients gastrointestinal ( GI ) tract disease , cause inability take oral medication , malabsorption syndrome , requirement intravenous ( IV ) alimentation , prior surgical procedure affect absorption , uncontrolled inflammatory GI disease ( e.g. , Crohn 's disease , ulcerative colitis ) 8 . Cardiopulmonary function criterion : • Current unstable arrhythmia require treatment • History symptomatic congestive heart failure • History myocardial infarction within 6 month enrollment • Current unstable angina • Family history long QT syndrome</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Myeloproliferative Diseases</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>MF</keyword>
	<keyword>Primary post essential thrombocythemia/polycythemia vera</keyword>
	<keyword>Ruxolitinib</keyword>
	<keyword>Jakafi</keyword>
	<keyword>INCB018424</keyword>
	<keyword>INC424</keyword>
	<keyword>Pracinostat</keyword>
	<keyword>Questionnaire</keyword>
	<keyword>Survey</keyword>
</DOC>